J D Wright1, T Ma, C K Chu, F D Boudinot. 1. Department of Pharmaceutics, College of Pharmacy, University of Georgia, Athens 30602, USA.
Abstract
PURPOSE: The objective of this study was to characterize the pharmacokinetics of 1-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (L-FMAU), a nucleoside analogue with potent activity against the hepatitis B virus and the Epstein-Barr virus, in rats. METHODS: Three doses of L-FMAU were administered intravenously (10, 25, and 50 mg/kg) to rats, and L-FMAU concentrations in plasma and urine were measured by HPLC. Pharmacokinetic parameters were generated by using area-moment analysis. RESULTS: There were no significant differences in the pharmacokinetic parameters between the three doses (alpha < 0.05). Thus, the disposition of L-FMAU was linear over the dosage of 10 to 50 mg/kg. Plasma concentrations of L-FMAU declined rapidly with a terminal phase half-life of 1.33 +/- 0.45 h (mean +/- SD). Total clearance of L-FMAU was moderate, averaging 1.15 +/- 0.28 L/h/kg. The fraction of compound excreted unchanged in urine was 0.59 +/- 0.13. No glucuronide metabolite was found in the urine. The steady-state volume of distribution was 1.12 +/- 0.26 L/kg indicating intracellular distribution of the compound. The fraction of L-FMAU bound to plasma proteins was approximately 15% and was independent of nucleoside concentration. CONCLUSIONS: The pharmacokinetics of L-FMAU in rats were independent of dose over the dosage range of 10 to 50 mg/kg.
PURPOSE: The objective of this study was to characterize the pharmacokinetics of 1-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (L-FMAU), a nucleoside analogue with potent activity against the hepatitis B virus and the Epstein-Barr virus, in rats. METHODS: Three doses of L-FMAU were administered intravenously (10, 25, and 50 mg/kg) to rats, and L-FMAU concentrations in plasma and urine were measured by HPLC. Pharmacokinetic parameters were generated by using area-moment analysis. RESULTS: There were no significant differences in the pharmacokinetic parameters between the three doses (alpha < 0.05). Thus, the disposition of L-FMAU was linear over the dosage of 10 to 50 mg/kg. Plasma concentrations of L-FMAU declined rapidly with a terminal phase half-life of 1.33 +/- 0.45 h (mean +/- SD). Total clearance of L-FMAU was moderate, averaging 1.15 +/- 0.28 L/h/kg. The fraction of compound excreted unchanged in urine was 0.59 +/- 0.13. No glucuronide metabolite was found in the urine. The steady-state volume of distribution was 1.12 +/- 0.26 L/kg indicating intracellular distribution of the compound. The fraction of L-FMAU bound to plasma proteins was approximately 15% and was independent of nucleoside concentration. CONCLUSIONS: The pharmacokinetics of L-FMAU in rats were independent of dose over the dosage range of 10 to 50 mg/kg.
Authors: C K Chu; T Ma; K Shanmuganathan; C Wang; Y Xiang; S B Pai; G Q Yao; J P Sommadossi; Y C Cheng Journal: Antimicrob Agents Chemother Date: 1995-04 Impact factor: 5.191
Authors: J L Abbruzzese; S Schmidt; M N Raber; J K Levy; A M Castellanos; S S Legha; I H Krakoff Journal: Invest New Drugs Date: 1989-07 Impact factor: 3.850
Authors: J W Witcher; F D Boudinot; B H Baldwin; M A Ascenzi; B C Tennant; J F Du; C K Chu Journal: Antimicrob Agents Chemother Date: 1997-10 Impact factor: 5.191
Authors: Ryuichi Nishii; Andrei Y Volgin; Osama Mawlawi; Uday Mukhopadhyay; Ashutosh Pal; William Bornmann; Juri G Gelovani; Mian M Alauddin Journal: Eur J Nucl Med Mol Imaging Date: 2007-12-04 Impact factor: 9.236